Fig. 1From: Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD studyThe primary outcome in participants randomized to the intensive compared with the standard blood glucose treatment group, stratified by HbA1c variability levelsBack to article page